Imatinib Mesylate: A Kinase Inhibitor
Created 2 weeks ago by anniepery

Imatinib, a kinase inhibitor that blocks a protein signal that causes cancer cell proliferation used to treat patients with hematological malignancies or malignant sarcomas. The imatinib medical uses include chronic myeloid leukemia in blast crisis, Ph+ chronic myeloid leukemia, acute lymphoblastic leukemia, aggressive systemic mastocytosis, gastrointestinal stromal tumors (GIST), and other diseases. The prescribed dose of imatinib should be administered by mouth, through a meal, and a large glass of water. Doses of imatinib 400 mg or 600 mg should be administered once a day, whereas a dose of imatinib 800 mg should be administered as 400 mg twice daily.